2025-09-18
Tofacitinib citrateEst bene agnita activae pharmaceutical ingredient (API) in curatio de autoimmune conditionibus. Cum crescente global demanda pro innovative therapies quod potest efficaciter administrare longis morbo, quod interest in hoc compositis habet significantly augeri. Jiangsu Run'an Pharmaceutical Co. Ltd. dictum dicata ad investigationem, progressionem et vestibulum summus qualitas pharmaceutical intermedia et apis, cursus Tofacitin citrate produci sub nomine occurrit internationalis qualitas.
In hoc articulo, nos de in detail characteres, parametri, momenti, et applications of Tofacitinib citrate. Praeterea, vos mos reperio technica specifications, a exstructa Overview ex eius beneficia, et responsa ad aliqui saepe interrogavit quaestiones providere comprehensive prudentia in hoc productum.
De momenti Tofacitinib citrate mendacium in unique mechanism agendi. Pertinet ad Janum Kinase (Jak) inhibitors familia, quae specie peltas meatus responsible pro immune responsio ordinacione. Hoc praecipue efficacius autoimmune morbo ut Rheumatoid arthritis, psoriatic arthritis, et ulcerative colitis.
Eius pharmaceutical relevance est auctus per:
Targeted mechanism: Reduces in stupore immune respondeo dum minimizing immunosuppression.
Probatur C. Usus: Late studuit et probatus in multis global mercatis.
Princeps therapeutic demanda: Increasing invaluisset autoimmune morbo boosts diu term demanda.
Reliable vestibulum: Stricta obsequio cum GMP ensures consistent qualis.
Infra est a technica summary nostriTofacitinib citrateSpecifications. Jiangsu Run'an Pharmaceutical Co. Ltd. ensures ut quisque batch obsequitur cum restrictius qualitas et puritas guidelines.
Generalis parametri
Product Name: Tofacitinib citrate
Forma: Alba ad off-album crystalline pulveris
MOLECULA: C₁₆h₂₀n₆o · c₆h₈o₇
Pondus: 504.5 g / mol
Cas numerum: 540737-29-9
Qualitas vexillum: In-Domus / Customized per client petitionem
Packaging: Available in fibra tympanis, duplex-layer polyethylene sacculos, aut customized solutions
Typical technica cubits
Parameter | Specificatio |
---|---|
Species | Alba ad off-album pulveris |
Asay (HPLC) | ≥ 99.0% |
Idem | Complies cum vexillum references |
Damnum siccatio | ≤ 0.5% |
RELICTUM solvents | Ichich Q3C guidelines |
Gravis metalla | ≤ X PPM |
Related substantias | ≤ 0.2% (una impuritas) |
Repono condicionem | Store in a frigus, sicco et tenebris est |
PLUTEUM vitae | XXIV menses in commendatur repono |
Dum eligendo pharmaceutical elit, tam qualitas et reliability sunt crucial. Jiangsu Run'an Pharmaceutical Co. Ltd. ensures sequenti commoda clients Worldwide:
Princeps castitatis levels- Achieving Assys ≥ 99.0% ensures maximum efficientiam in formula.
Global signa- productio facilities propinquos meos cum CGMP guidelines et internationales normas.
Supplementum- robust faciens facultatem praestet certa partus.
Customized packaging- Flexibile Packaging Solutions Tailored ad Client Morsus Mihi.
Support technica- Dedicated Support Team providet detailed productum documenta et coas.
Tofacitinib citrate late usus est per diversas medicinales areas, cum primaria munus in:
Rheumatoid arthritis- adjuvat levare iuncturam dolor, tumor et rigoremque.
Psoriatic arthritis- improves corporis munus et reduces cutis-related symptoms.
Ulcerative colitis- praebet remissionem et sustentationem Lorem pro inveterata alvus inflammatio.
Research ongoing- Investigavit ad alia autoimmune perturbationes, exclusit futurum potentiale.
Et crescente adoptionem de oris Jak inhibitors extollere opportuna partes Tofacitinib citrate in pharmaceutical industria.
Q1: Quid est ToFacitinib citrate maxime propter?
A1: Tofacitinib citrate est praesertim usus est activa pharmaceutical ingrediens in medications disposito tractare autoimmune morbo ut RHEUMATIS Arthritis, PSoriatic arthritis, et ulcerative COLITIS. Eius munus in Jak inhibitor concedit ut control immunes obruit efficaciter.
Q2: Quomodo debet ToFacitinib citrate repono ponere eius stabilitatem?
A2: Non debet condita in a frigus, arida, et bene uentilandam environment, a recta lucem et calorem. Propriis repono sub moderari condiciones ensures a fasciae vita XXIV menses.
Q3: Quid qualitas signa facit Jiangsu run'an pharmaceutical Co. Ltd. sequere in producendo Tofacitinib citrate?
A3: nostri facilities stricte propinquos meos CGMP signa, dum productio est monitored sub rigorous qualis imperium systems. Quisque batch est probata pro puritate, et salus parametri, cum libellorum analysis provisum clients.
Q4: Can Jiangsu Run'an Pharmaceutical Co. Ltd. providere Lorem Packaging vel specifica grades?
A4: Etiam. Nos intelligere quod quisque client habet unicum requisitis, ita providere flexibilia packaging options et scissor-in specifications secundum clientem project.
Jiangsu Run'an Pharmaceutical Co. Ltd. statutum est fama et tradens summus qualitas pharmaceutical ingredientia ad global sociis. Per focusing in qualis fide, mos servitium, et innovation, ut diu terminus cooperante et fiducia.
Cum vis nobisTofacitinib citrateTu es eligens:
Constantia in qualitate et perficientur
Internationalis obsequium et certificaciones
Certa socium copia catena stabilitatem
Professional Support pro omnibus technica et documenta necessitates
Tofacitinib citrate factus est in angulari in progressionem therapies targeting autoimmune morbo. Et efficaciam, combined cum praecisioneJiangsu Run'an Pharmaceutical Co. Ltd.'S signa facit, facit eam a dato ad pharmaceutical turmas worldwide.
Nam ulteriores notitia, technica documenta, aut collaboration occasiones, velitcontactusUS directe.